Kenvue Inc. (NYSE:KVUE) Shares Sold by RNC Capital Management LLC

RNC Capital Management LLC lessened its position in Kenvue Inc. (NYSE:KVUE) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,886,566 shares of the company’s stock after selling 54,587 shares during the period. Kenvue comprises 2.2% of RNC Capital Management LLC’s portfolio, making the stock its 21st largest holding. RNC Capital Management LLC owned approximately 0.10% of Kenvue worth $40,278,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Grove Bank & Trust raised its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Riverview Trust Co purchased a new position in shares of Kenvue in the 3rd quarter worth $30,000. Geneos Wealth Management Inc. purchased a new stake in Kenvue during the fourth quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in Kenvue during the third quarter valued at about $35,000. Finally, Fortitude Family Office LLC raised its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on KVUE shares. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group cut their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. JPMorgan Chase & Co. increased their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Bank of America boosted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Price Performance

Shares of KVUE stock opened at $19.78 on Friday. The firm has a market cap of $37.93 billion, a P/E ratio of 35.97, a P/E/G ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a fifty day moving average of $21.70 and a two-hundred day moving average of $21.95.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. As a group, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 4.15%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.